hnf1bb Antibody

What is HNF1B and why is it important in research?

HNF1B (also known as TCF2, FJHN, HNF-1-beta) is a homeobox transcription factor that plays crucial roles in organ development, particularly in the kidney, liver, pancreas, and reproductive organs. The protein is approximately 61.3 kilodaltons in mass and functions as a regulator of gene expression during embryonic development and in adult tissues . Research on HNF1B is significant because mutations in this gene are associated with various diseases including renal cysts and diabetes syndrome (RCAD), certain types of cancer, and developmental abnormalities. Antibodies against HNF1B are essential tools for studying its expression, localization, protein interactions, and roles in both normal development and disease states.

What species reactivity is available for HNF1B antibodies?

HNF1B antibodies are available with reactivity to multiple species, allowing for comparative studies across evolutionary lines. Based on current commercial offerings, researchers can obtain antibodies with the following reactivity profiles:

• Human-specific antibodies

• Human, mouse, and rat cross-reactive antibodies

• Broader reactivity profiles including bovine, dog, guinea pig, hamster, and zebrafish

When selecting an antibody for cross-species studies, it's advisable to verify the conservation of the target epitope sequence across the species of interest. Many antibodies that claim multi-species reactivity are raised against highly conserved regions of the protein, but experimental validation in your specific model organism remains essential.

What applications are most common for HNF1B antibodies?

HNF1B antibodies have been validated for numerous research applications, with varying degrees of optimization for each technique:

Researchers should select antibodies specifically validated for their intended application, as performance can vary significantly between techniques even with the same antibody .

How do I choose between polyclonal and monoclonal HNF1B antibodies?

The choice between polyclonal and monoclonal antibodies depends on your experimental goals:

Polyclonal HNF1B Antibodies:

• Recognize multiple epitopes on the HNF1B protein

• Generally provide stronger signals due to multiple binding sites

• Useful for detection of denatured proteins (Western blot)

• More tolerant of minor protein changes or polymorphisms

• Greater batch-to-batch variation

Monoclonal HNF1B Antibodies:

• Recognize a single epitope with high specificity

• Consistent performance across batches

• Lower background in most applications

• Better for distinguishing between closely related proteins

• May be more sensitive to epitope masking due to protein modifications

For critical experiments requiring reproducibility over time, monoclonal antibodies like the rabbit monoclonal anti-HNF1B [Clone ID: LBIR4F6] or the [EPR6334(2)] clone may provide more consistent results . For maximum sensitivity in detecting low-abundance HNF1B, polyclonal antibodies might be preferable, especially when signal strength is paramount.

What controls should I include when using HNF1B antibodies?

Proper controls are essential for interpreting HNF1B antibody results:

Positive Controls:

• Cell lines with known HNF1B expression (e.g., HepG2, kidney epithelial cells)

• Tissue sections from organs with established HNF1B expression (kidney, liver, pancreas)

• Recombinant HNF1B protein (for Western blot)

Negative Controls:

• Cell lines with confirmed absence or knockdown of HNF1B

• Isotype control antibodies matching your primary antibody

• Primary antibody omission controls

• Competitive blocking with immunizing peptide

• CRISPR/siRNA knockdown tissues or cells

Specificity Controls:

• Testing on Western blots to confirm correct molecular weight (61.3 kDa)

• Testing multiple antibodies targeting different regions of HNF1B

• Correlation with mRNA expression data

The inclusion of these controls helps distinguish specific signals from non-specific background and validates the antibody performance in your specific experimental system.

What is the optimal sample preparation for HNF1B detection?

Sample preparation significantly impacts HNF1B antibody performance across different applications:

For Western Blot:

• Complete lysis using RIPA or NP-40 buffers containing protease inhibitors

• Sample denaturation at 95°C for 5 minutes in reducing conditions

• Fresh preparation of lysates recommended

• Nuclear extraction protocols may improve detection of this transcription factor

For Immunohistochemistry:

• 10% neutral-buffered formalin fixation (12-24 hours)

• Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• For frozen sections, acetone or methanol fixation (10 minutes)

• Blocking with 5-10% normal serum from the species of the secondary antibody

For Immunocytochemistry/Immunofluorescence:

• 4% paraformaldehyde fixation (10-15 minutes)

• Permeabilization with 0.1-0.3% Triton X-100

• Antigen retrieval may improve nuclear staining

• Blocking with BSA or normal serum

Optimization of these protocols for your specific sample type and antibody is often necessary to achieve optimal results.

Why might I see weak or absent signal with HNF1B antibodies?

Several factors can contribute to poor signal when using HNF1B antibodies:

Technical Factors:

• Insufficient antibody concentration (try titrating from 1:100 to 1:1000)

• Inadequate antigen retrieval for fixed tissues or cells

• Overfixation masking epitopes

• Buffer incompatibility

• Protein degradation during sample preparation

• Secondary antibody mismatch

Biological Factors:

• Low HNF1B expression in your sample

• Post-translational modifications affecting epitope recognition

• Splice variants lacking the epitope

• Protein-protein interactions masking the epitope

• Nuclear localization requiring specialized extraction

Methodological Approaches to Improve Signal:

• Increase antibody concentration or incubation time

• Try different antigen retrieval methods (citrate vs. EDTA buffers)

• Test alternative antibodies targeting different epitopes

• Use signal amplification systems (HRP polymers, tyramide)

• For Western blots, load more protein and optimize transfer conditions

• For IHC/ICC, reduce washing stringency and optimize blocking

Testing the antibody on a known positive control sample is essential to distinguish between technical issues and true biological absence of the target.

How can I reduce background when using HNF1B antibodies?

High background is a common challenge when working with nuclear transcription factor antibodies like HNF1B:

Common Causes of Background:

• Excessive antibody concentration

• Insufficient blocking

• Cross-reactivity with related proteins

• Non-specific binding to cell components

• Endogenous peroxidase/phosphatase activity

• Inappropriate secondary antibody dilution

Strategies to Reduce Background:

• Titrate primary antibody to find optimal concentration

• Extend blocking time (2 hours at room temperature or overnight at 4°C)

• Test alternative blocking agents (5% BSA, 5-10% normal serum, commercial blockers)

• Include 0.1-0.3% Triton X-100 or Tween-20 in washing buffers

• Add 0.1-0.3M NaCl to washing buffers to increase stringency

• Pre-absorb the primary antibody with tissue powder

• For IHC, quench endogenous peroxidase with 3% H₂O₂ before antibody incubation

• Use more specific detection systems (polymer-based vs. ABC method)

Monoclonal antibodies generally produce less background than polyclonal antibodies but may require more optimization of antigen retrieval methods.

How do I validate the specificity of HNF1B antibodies?

Rigorous validation is essential to ensure HNF1B antibody specificity:

Western Blot Validation:

• Confirm single band at expected molecular weight (61.3 kDa)

• Test on positive and negative control samples

• Perform peptide competition assays

• Compare multiple antibodies against different epitopes

Genetic Validation:

• Test on samples with CRISPR/Cas9 knockout of HNF1B

• Use siRNA or shRNA knockdown samples

• Test on samples with known HNF1B mutations

• Correlation with HNF1B mRNA expression levels

Immunohistochemistry Validation:

• Compare staining pattern with published HNF1B localization

• Verify nuclear localization consistent with transcription factor function

• Test on tissue panels with known HNF1B expression profiles

• Confirm absence of staining in negative control tissues

Cross-Platform Validation:

• Correlate results between techniques (WB, IHC, IF)

• Compare with in situ hybridization for mRNA localization

• Validate findings using orthogonal methods (ChIP-seq, RNA-seq)

Many commercial HNF1B antibodies have citation records that can provide information about validated applications and experimental conditions .

How can I use HNF1B antibodies in chromatin immunoprecipitation (ChIP) assays?

ChIP assays with HNF1B antibodies allow researchers to identify DNA binding sites and study transcriptional regulation:

Recommended Protocol:

• Cross-link protein-DNA complexes in cells using 1% formaldehyde (10 minutes)

• Lyse cells and sonicate chromatin to 200-500 bp fragments

• Pre-clear lysate with protein A/G beads

• Immunoprecipitate with 2-5 μg of ChIP-validated HNF1B antibody overnight at 4°C

• Capture antibody-protein-DNA complexes with protein A/G beads

• Wash stringently to remove non-specific interactions

• Reverse cross-links and purify DNA

• Analyze by qPCR for known targets or sequence for genome-wide binding sites

Critical Considerations:

• Select antibodies specifically validated for ChIP applications

• Include IgG control and input samples

• Validate enrichment at known HNF1B binding sites

• Optimize sonication conditions for your cell type

• Consider ChIP-seq for genome-wide binding analysis

Several HNF1B antibodies have been cited in ChIP studies, including the Novus Biologicals TCF-2/HNF-1 beta Antibody which has ChIP listed among its applications .

What is the role of HNF1B in disease research?

HNF1B antibodies are valuable tools in studying various disease states:

Renal Diseases:

• HNF1B mutations cause renal cysts and diabetes syndrome (RCAD)

• Antibodies help characterize expression patterns in normal vs. cystic kidney tissues

• Useful for studying tubular development and cystogenesis

Cancer Research:

• HNF1B is implicated in ovarian clear cell carcinoma, prostate cancer, and renal cell carcinoma

• Serves as a diagnostic marker in some cancer subtypes

• Antibodies help evaluate expression changes during carcinogenesis

Diabetes Research:

• HNF1B mutations are associated with maturity-onset diabetes of the young (MODY5)

• Antibodies help study pancreatic development and β-cell function

• Useful for investigating transcriptional networks in glucose metabolism

Developmental Biology:

• Essential for studying organogenesis of liver, pancreas, kidney, and reproductive tract

• Antibodies track expression patterns during embryonic development

• Useful for lineage tracing experiments

Researchers should select antibodies with demonstrated specificity in the relevant disease model and consider using multiple antibodies targeting different epitopes for confirmation of findings.

How can I use HNF1B antibodies in multiplex immunofluorescence?

Multiplex immunofluorescence allows simultaneous detection of HNF1B with other proteins:

Protocol Recommendations:

• Select HNF1B antibodies raised in different host species from other target antibodies

• Alternatively, use directly conjugated antibodies (several vendors offer conjugated HNF1B antibodies)

• Optimize each antibody individually before combining

• Use sequential staining protocols for same-species antibodies

• Consider tyramide signal amplification for weak signals

• Include appropriate controls for each antibody and fluorophore

Antibody Selection Considerations:

• Use monoclonal antibodies when possible to reduce cross-reactivity

• Verify antibody performance in singleplex before multiplexing

• Check for potential cross-reactivity between secondary antibodies

• Consider spectral unmixing capabilities of your imaging system

Available Conjugated Options:
Several vendors offer HNF1B antibodies with direct conjugation to fluorophores such as:

• Cy3

• DyLight 488

• FITC

• Alexa Fluors

BosterBio, for example, offers their Anti-HNF1 beta/HNF1B Antibody with various conjugate options including Biotin, Cy3, and DyLight488, which can simplify multiplex protocols .

How do post-translational modifications affect HNF1B antibody recognition?

HNF1B undergoes several post-translational modifications that can impact antibody recognition:

Known Modifications:

• Phosphorylation at multiple serine/threonine residues

• SUMOylation

• Ubiquitination regulating protein stability

• Potential acetylation and methylation

Impact on Antibody Detection:

• Modification-sensitive antibodies may show variable detection depending on cellular context

• Epitopes containing modification sites may be masked or exposed

• Some modifications alter protein conformation affecting distant epitopes

• Modifications can change HNF1B mobility on SDS-PAGE gels

Strategies for Comprehensive Detection:

• Use antibodies targeting different regions of HNF1B

• Compare N-terminal vs. C-terminal targeting antibodies

• Consider phospho-specific antibodies when studying signaling

• Treat samples with phosphatases before Western blot if phosphorylation is suspected to affect detection

• Compare native vs. denaturing conditions

Several vendors offer antibodies targeting different regions of HNF1B, including N-terminal specific antibodies like Aviva Systems Biology's HNF1B antibody (ARP32320_P050) and C-terminal specific antibodies like their ARP34011_P050 product .

What are optimal dilution ranges for HNF1B antibodies in different applications?

Proper antibody dilution is crucial for balancing specific signal and background:

These ranges serve as starting points, and optimization for your specific:

• Antibody lot

• Sample type

• Detection system

• Fixation method

• Blocking reagents

Is essential for optimal results. Some antibody suppliers provide lot-specific recommended dilutions that should be consulted first .

What cell lines and tissues are best for studying HNF1B expression?

Selecting appropriate biological models is crucial for HNF1B research:

Cell Lines with Endogenous HNF1B Expression:

• HepG2 (human liver hepatocellular carcinoma)

• HK-2 (human kidney proximal tubule)

• HPDE (human pancreatic ductal epithelial cells)

• OVCAR3 (ovarian cancer cell line)

• mIMCD3 (mouse inner medullary collecting duct)

Tissues with High HNF1B Expression:

• Kidney (proximal tubules, collecting ducts)

• Liver (hepatocytes)

• Pancreas (ductal cells)

• Reproductive tract (endometrium, prostate)

• Developing embryonic tissues of these organs

Experimental Models:

• Transgenic mice with HNF1B mutations or conditional knockout

• Zebrafish models for developmental studies

• Organoid cultures from kidney, liver, or pancreas

• Patient-derived xenografts from HNF1B-associated cancers

When validating a new HNF1B antibody, testing on multiple positive control cell lines or tissues is recommended to confirm consistent detection patterns across different biological contexts.

How can I optimize Western blot conditions for HNF1B detection?

Western blot optimization for HNF1B requires attention to several parameters:

Sample Preparation:

• Use RIPA buffer with protease inhibitors for total protein extraction

• Consider nuclear extraction protocols for enrichment

• Avoid repeated freeze-thaw cycles

• Use fresh lysates when possible

Gel Electrophoresis:

• 8-10% SDS-PAGE gels provide good resolution around 61.3 kDa

• Load 20-50 μg of total protein per lane

• Include molecular weight markers that span 50-75 kDa range

Transfer Conditions:

• Semi-dry or wet transfer systems both work

• Transfer at 100V for 1 hour or 30V overnight for larger proteins

• Use PVDF membranes for better protein retention

• Verify transfer efficiency with reversible stains

Antibody Incubation:

• Block with 5% non-fat dry milk or 5% BSA in TBST

• Incubate primary antibody overnight at 4°C

• Use antibody dilutions recommended for Western blot (typically 1:500-1:2000)

• Wash extensively (4 × 5 minutes) with TBST

Detection:

• HRP-conjugated secondary antibodies with ECL detection

• Consider enhanced chemiluminescent substrates for low abundance

• Optimize exposure times (start with 30 seconds to 5 minutes)

Based on the search results, antibodies from BosterBio, Aviva Systems Biology, and antibodies-online have been specifically validated for Western blot applications with HNF1B .

How can I use HNF1B antibodies to study protein-protein interactions?

HNF1B functions within protein complexes, making interaction studies valuable:

Co-Immunoprecipitation (Co-IP):

• Lyse cells in non-denaturing buffer (e.g., NP-40 buffer)

• Pre-clear lysate with protein A/G beads

• Incubate with 2-5 μg HNF1B antibody overnight at 4°C

• Capture complexes with protein A/G beads

• Wash under gentle conditions to preserve interactions

• Elute and analyze interacting proteins by Western blot or mass spectrometry

Proximity Ligation Assay (PLA):

• Fix and permeabilize cells/tissues

• Incubate with HNF1B antibody and antibody against potential interacting protein

• Add PLA probes with oligonucleotide-linked secondary antibodies

• Perform ligation and rolling circle amplification

• Detect fluorescent signal indicating proteins within 40 nm proximity

Förster Resonance Energy Transfer (FRET):

• Label HNF1B antibody with donor fluorophore

• Label interacting protein antibody with acceptor fluorophore

• Measure energy transfer indicating close proximity

Santa Cruz Biotechnology's HNF-1β antibodies have been cited in immunoprecipitation studies, suggesting their suitability for protein interaction research .

What are emerging applications for HNF1B antibodies in research?

HNF1B antibodies are finding utility in advancing research areas:

Single-Cell Analysis:

• Combining HNF1B antibodies with single-cell technologies

• Mass cytometry (CyTOF) incorporating HNF1B detection

• Single-cell Western blot systems

3D Tissue Imaging:

• Clearing techniques combined with HNF1B immunostaining

• Light-sheet microscopy of embryonic development

• Whole-organ mapping of HNF1B expression patterns

Spatial Transcriptomics Integration:

• Correlating HNF1B protein localization with transcriptomic profiles

• Combining immunofluorescence with in situ sequencing

Genome Editing Validation:

• Confirming CRISPR/Cas9 editing of HNF1B locus

• Assessing protein knockout efficiency

• Studying consequences of HNF1B mutations

Therapeutic Development:

• Validating HNF1B modulation in disease models

• Screening for compounds affecting HNF1B expression or activity

• Developing diagnostics for HNF1B-associated diseases

As these techniques advance, antibody selection criteria will increasingly include compatibility with specialized applications beyond traditional methods.

How do HNF1B antibody results correlate with genetic and transcriptomic data?

Integrating multi-omic data provides comprehensive understanding:

Correlation with Genetic Variation:

• HNF1B antibodies can detect protein-level consequences of genetic variants

• Particularly valuable for studying missense mutations that preserve protein expression

• May reveal unexpected post-transcriptional regulation

Transcriptomic Integration:

• Comparing HNF1B protein levels with mRNA expression

• Identifying discrepancies suggesting post-transcriptional regulation

• Correlating HNF1B binding (ChIP-seq) with gene expression changes

Methodological Approaches:

• Parallel analysis of DNA sequencing, RNA-seq, and protein detection

• Western blot quantification normalized to housekeeping proteins

• Immunofluorescence intensity quantification

• Correlation analysis between protein and mRNA levels

• Validation of ChIP-seq findings with reporter assays

This integrated approach is particularly valuable for studying HNF1B's role in development and disease, where genetic variants may have complex effects on protein function that aren't captured by expression analysis alone.